“…Another layer of complexity is added by the incorporation of Vps37 proteins into ESCRT-I to form functionally distinct complexes in the cell (Stefani et al, 2011;Wunderley et al, 2014). Changes in mRNA and protein levels of VPS37A were previously documented in various cancer types, including liver, prostate, breast, ovarian, renal, lung, glioma, gastric, oral and oropharyngeal squamous cell carcinoma and colon cancer (Chen et al, 2015;Chen et al, 2020;Chen et al, 2018;Du et al, 2016;Fu et al, 2018;Lai et al, 2009;Perisanidis et al, 2013;Sun et al, 2017;Vasaikar et al, 2019;Wittinger et al, 2011;Wu et al, 2019;Xu et al, 2017a;Xu et al, 2017b;Xu et al, 2014;Xu et al, 2017c;Xu et al, 2003;Yang et al, 2016;Yang et al, 2017;Zhu et al, 2015). Several of these studies suggested that VPS37A acts as a tumor suppressor and its loss can serve as an adverse prognostic factor.…”